Episode 24: Dr. Bas Groot Koerkamp—Clinical Trials in Pancreatic Cancer and The Dutch Pancreatic Cancer Group
Manage episode 410763800 series 2966292
Today’s episode is a special in-person interview with Dr. Newhook and Dr. Bas Groot Koerkamp! Dr. Koerkamp is a hepatobiliary surgeon and researcher within the HPB and Transplantation Surgery department of Erasmus University Medical Center in Rotterdam, Netherlands. Dr. Groot Koerkamp leads several national clinical studies with the Dutch Pancreatic Cancer Group, including the PREOPANC studies, which we are thrilled to discuss in today’s episode! Enjoy!
Papers Referenced in the Episode:
- Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Tienhoven G, van Eijck CHJ; Dutch Pancreatic Cancer Group. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27. PMID: 35084987.
- Janssen, Q.P., van Dam, J.L., Bonsing, B.A. et al.Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21, 300 (2021). https://doi.org/10.1186/s12885-021-08031-z
- Janssen, Q., van Dam, J. L., Besselink, M. G., Homs, M. Y., van Tienhoven, G., Wilmink, J. W., ... & Dutch Pancreatic Cancer Group. (2021). Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
- Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, van Eijck CHJ, de Hingh IHJT, Karsten TM, van der Kolk MB, Patijn GA, Liem MSL, van Santvoort HC, Loosveld OJL, de Vos-Geelen J, Zonderhuis BM, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z. PMID: 33757440; PMCID: PMC7989075.
- Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G; Dutch Pancreatic Cancer Group. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27. PMID: 32105518; PMCID: PMC8265386.
- https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/july-2022-volume-107-number-7/alliance-a021806-a-phase-iii-trial-of-perioperative-vs-adjuvant-chemotherapy-for-resectable-pancreatic-cancer/
- Franssen, S., Van Driel, L. M., Moelker, A., & Groot Koerkamp, B. (2023). Primary percutaneous stenting above the ampulla for palliative biliary drainage of malignant hilar biliary obstruction.
69 επεισόδια